Discover trends, market shifts, and competitive outlooks for the imfinzi (durvalumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Imfinzi (durvalumab) Market Size Shifted, And What Is the Outlook Through 2034?

In recent years, the market size for imfinzi (durvalumab) has seen speedy expansion. It is projected to increase from $2,701.22 million in 2024 to $3,013.33 million in 2025, marking a compound annual growth rate (CAGR) of 11.6%. This marked rise during the historical period can be traced to expansions in indications and approvals, the surge in demand for targeted treatments, an upward trend in patient preference for personalized treatments, advancements in immunotherapy, and heightened patient demand for immunotherapies.

Expectations are high for significant growth in the Imfinzi (Durvalumab) market in the coming years, with a projected value of $4,143.36 million in 2029 from a compound annual growth rate (CAGR) of 11.3%. This predicted expansion during the forecasted period is linked to multiple factors including the increasing use of combination therapies, the escalation in pharmaceutical research and development, the rising incidence of cancer, the growing acceptance of immunotherapy, expanding regulatory footprint, and heightened investment in healthcare facilities. Further influencing this forecasted growth are major trends including the implementation of personalized medicine techniques, a shift towards individualized medicine, the embracing of biosimilars, the integration of revolutionary AI and machine learning technologies and strategic collaborations between pharmaceutical companies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Imfinzi (durvalumab) Market?

The increasing cases of cancer are anticipated to fuel the Imfinzi (durvalumab) market. Disease such as cancer is characterized by uncontrolled cell overgrowth and spreading destructive to the normal body tissues. Spurring cases of cancer is largely attributed to aging, as cancer risk correlates with age, alongside lifestyle choices such as habitual smoking, unhealthy diet and obesity that heighten the probability of cancer. Imfinzi (durvalumab) works in treating cancer by impeding the PD-L1 protein which helps cancer cells avoid the immune system’s detection. As per the data by the National Cancer Institute (NIH), a US government organization, as of 2024, the number of cancer survivors in the U.S. in 2022 were 18.1 million and this figures are projected to increase to 22.5 million by 2032. Hence, the escalating rates of cancer bolster the expansion of the Imfinzi (durvalumab) market. The Upturn of Personalized Medicine Giving Rise to the Imfinzi (durvalumab) Market

Which Primary Segments of the Imfinzi (durvalumab) Market Are Driving Growth and Industry Transformations?

The imfinzi (durvalumab)market covered in this report is segmented –

1) By Type: 2.4mL Injection; 10mL Injection

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Which Regions Are Key Players in the Growth of the Imfinzi (durvalumab) Market?

North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market is majorly influenced by a trend that involves gaining government health agencies’ approvals to widen its use for various cancer types, enhance its clinical implications, and boost its market presence. Such regulatory approvals are officially issued by health authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), allowing the marketing and utilization of a specific medical product in certain regions. For example, AstraZeneca, an established pharmaceutical company from the UK, secured the FDA’s approval for durvalumab (Imfinzi) as a treatment for localized or metastatic biliary tract cancer (BTC) in adults in September 2022. The approval was based on the results from the crucial TOPAZ-1 study. This study showed that durvalumab, when used with gemcitabine and cisplatin, considerably enhanced patients’ overall survival (12.8 months against 11.5 months for placebo) and progression-free survival (7.2 months against 5.7 months). The research enrolled 685 patients afflicted with different BTC forms, with fatigue, nausea, and abdominal pain being common side effects. Durvalumab’s recommended dosage is 1,500 mg every three weeks during the combination therapy, followed by a monotherapy every four weeks.

View the full report here:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

What Parameters Are Used to Define the Imfinzi (durvalumab) Market?

Imfinzi (durvalumab) is a human monoclonal antibody and an immunotherapy drug specifically designed to block programmed death-ligand 1 (PD-L1), a protein that tumors use to evade detection by the immune system. It is used to treat various cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model